<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="hep41480-tbl-0002" xml:lang="en" orientation="portrait" position="float">
 <label>Table 2</label>
 <caption>
  <p>Recommended Treatments for Chronic HCV Infection
   <xref ref-type="fn" rid="hep41480-note-0006">*</xref>
  </p>
 </caption>
 <table frame="hsides" rules="groups">
  <col style="border-right:solid 1px #000000" span="1"/>
  <col style="border-right:solid 1px #000000" span="1"/>
  <col style="border-right:solid 1px #000000" span="1"/>
  <col style="border-right:solid 1px #000000" span="1"/>
  <col style="border-right:solid 1px #000000" span="1"/>
  <col style="border-right:solid 1px #000000" span="1"/>
  <thead valign="top">
   <tr style="border-bottom:solid 1px #000000">
    <th align="left" valign="top" rowspan="1" colspan="1">Regimen</th>
    <th align="center" valign="top" rowspan="1" colspan="1">Treated Genotypes</th>
    <th align="center" valign="top" rowspan="1" colspan="1">Duration (weeks)</th>
    <th align="center" valign="top" rowspan="1" colspan="1">Efficacy</th>
    <th align="center" valign="top" rowspan="1" colspan="1">Treatable Special Populations</th>
    <th align="center" valign="top" rowspan="1" colspan="1">Special Considerations</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left" rowspan="3" colspan="1">Daclatasvir/sofosbuvir</td>
    <td align="center" rowspan="3" colspan="1">1, 2, 3, 4</td>
    <td align="center" rowspan="3" colspan="1">12</td>
    <td align="center" rowspan="3" colspan="1">93%‐100%</td>
    <td align="left" rowspan="1" colspan="1">Decompensated cirrhosis</td>
    <td align="left" rowspan="3" colspan="1">Add RBV for decompensated cirrhosis</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Following liver transplant with/without cirrhosis</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">HIV/HCV coinfection when antiretroviral cannot be changed to accommodate recommended regimens (GT1,4)</td>
   </tr>
   <tr>
    <td align="left" rowspan="3" colspan="1">Elbasvir/grazoprevir</td>
    <td align="center" rowspan="3" colspan="1">1, 3, 4</td>
    <td align="center" rowspan="3" colspan="1">12</td>
    <td align="center" rowspan="3" colspan="1">91%‐100%</td>
    <td align="left" rowspan="1" colspan="1">Treatment‐experienced (PEG/RBV) with/without cirrhosis</td>
    <td align="left" rowspan="1" colspan="1">GT1a: Alternative regimen if high‐fold resistance variants to NS5A</td>
   </tr>
   <tr>
    <td align="left" rowspan="2" colspan="1">Severe renal impairment</td>
    <td align="left" rowspan="1" colspan="1">GT3: Add sofosbuvir for PEG/RBV experienced with compensated cirrhosis</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Not for decompensated cirrhosis or following liver transplant with cirrhosis</td>
   </tr>
   <tr>
    <td align="left" rowspan="4" colspan="1">Glecaprevir/pibrentasvir</td>
    <td align="center" rowspan="4" colspan="1">1, 2, 3, 4, 5, or 6</td>
    <td align="center" rowspan="4" colspan="1">8</td>
    <td align="center" rowspan="4" colspan="1">94%‐100%</td>
    <td align="left" rowspan="1" colspan="1">Treatment‐experienced (PEG/RBV) with/without cirrhosis
     <xref ref-type="fn" rid="hep41480-note-0007">†</xref>
    </td>
    <td align="left" rowspan="1" colspan="1">Not for decompensated cirrhosis or following liver transplant with cirrhosis</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Following liver transplant without cirrhosis</td>
    <td align="left" rowspan="1" colspan="1">12‐week duration for special populations</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Severe renal impairment</td>
    <td align="left" rowspan="1" colspan="1">8‐week duration for compensated cirrhosis</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Following kidney transplant with/without cirrhosis</td>
    <td align="left" rowspan="1" colspan="1"/>
   </tr>
   <tr>
    <td align="left" rowspan="4" colspan="1">Ledipasvir/sofosbuvir</td>
    <td align="center" rowspan="4" colspan="1">1, 4, 5, or 6</td>
    <td align="center" rowspan="4" colspan="1">12</td>
    <td align="center" rowspan="4" colspan="1">93% to 100%</td>
    <td align="left" rowspan="1" colspan="1">PEG/RBV experienced with/without cirrhosis</td>
    <td align="left" rowspan="1" colspan="1">8‐week duration for treatment‐naïve, non‐black, HIV‐negative, HCV RNA &lt; 10
     <sup>6</sup> IU/mL, without cirrhosis
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Decompensated cirrhosis</td>
    <td align="left" rowspan="2" colspan="1">24‐week duration and add RBV for decompensated cirrhosis with sofosbuvir failure</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Following liver transplant with/without cirrhosis (compensated or decompensated)</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Following kidney transplant with/without cirrhosis</td>
    <td align="left" rowspan="1" colspan="1">Add RBV for decompensated cirrhosis, following liver transplant</td>
   </tr>
   <tr>
    <td align="left" rowspan="3" colspan="1">Sofosbuvir/velpatasvir</td>
    <td align="center" rowspan="3" colspan="1">1, 2, 3, 4, 5, or 6</td>
    <td align="center" rowspan="3" colspan="1">12</td>
    <td align="center" rowspan="3" colspan="1">96%‐100%</td>
    <td align="left" rowspan="1" colspan="1">Treatment‐naïve, PEG/RBV, or DAA experienced without cirrhosis (± decompensation)</td>
    <td align="left" rowspan="1" colspan="1">Add voxilaprevir for NS5A failure (including NS3 protease inhibitors) with/without cirrhosis (not for decompensated cirrhosis or following liver transplant with cirrhosis)</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">PEG/RBV with/without NS3 protease inhibitor experienced</td>
    <td align="left" rowspan="2" colspan="1">24‐week duration and add RBV for decompensated cirrhosis with DAA failure including NS5A</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Following liver transplant with decompensated cirrhosis</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot id="hep41480-ntgp-0003">
  <fn id="hep41480-note-0006">
   <label>*</label>
   <p>Simplified regimen for treatment‐naïve, nonpregnant patient with normal renal function and HCV mono‐infection, without cirrhosis or history of liver transplantation: glecaprevir/pibrentasvir for 8 weeks or sofosbuvir/velpatasvir for 12 weeks.</p>
  </fn>
  <fn id="hep41480-note-0007">
   <label>
    <sup>†</sup>
   </label>
   <p>Also non‐NS5A failure with/without cirrhosis.</p>
  </fn>
  <fn id="hep41480-note-0008">
   <p>Abbreviations: CKD, chronic kidney disease; PEG, pegylated interferon; RBV, ribavirin.</p>
  </fn>
 </table-wrap-foot>
 <permissions>
  <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
 </permissions>
</table-wrap>
